FDA To “Revisit” Intravenous Immune Globulin Clinical Trial Design
FDA will revisit its intravenous immune globulin Phase III clinical trial design recommendations in light of decreased adverse event rates for the therapies
You may also be interested in...
Clinical trials for intravenous immune globulin products can be "non-inferiority" studies, Center for Biologics Evaluation & Research Hematology Division Deputy Director Basil Golding, MD, told the Blood Products Advisory Committee.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials